AI isn’t close to curing cancer. This startup says it knows what it will take.TechCrunch·15 hours ago
Oncoinvent publishes investor presentation on Radspherin alpha therapy for peritoneal metastasesPUBT·19 hours ago
Conexeu says CXU preclinical program completes 12-month P..O.F. phase, meets objectivesPUBT·1 day ago, 07:55 AMCNXU-10.31%
REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0Earnings Watch·May 6 at 03:13 PMRVMDW-1.07%
